Welcome!

News Feed Item

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

Summary

GBI Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019". There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

Scope

- A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
- In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
- Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers and barriers for market growth

Reasons to buy

- Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
- Understand the strengths and weaknesses of each product
- Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

Table of Contents

1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Epidemiology 10
2.2 Symptoms 10
2.3 Etiology 11
2.4 Pathophysiology 11
2.5 Co-morbidities and Complications 12
2.6 Classification 13
2.7 Prognosis 14
2.8 Diagnosis 14
2.9 Assessing Treatment Effectiveness 16
2.10 Treatment Algorithm 16
2.10.1 The Role of Insulin in Type 2 Diabetes 18
2.10.2 Non-insulin Diabetic Drugs 19
2.10.3 Other Drugs 21
3 Key Marketed Products 22
3.1 Metformin 22
3.2 DPP-4 Inhibitors 23
3.2.1 Januvia (sitagliptin) – Merck & Co 23
3.2.2 Tradjenta (linagliptin) – Boehringer Ingelheim 24
3.2.3 Onglyza (saxagliptin) – Bristol-Myers Squibb and AstraZeneca 25
3.2.4 Nesina (alogliptin) – Takeda 25
3.2.5 Galvus (vildagliptin) – Novartis 26
3.2.6 Tenelia (teneligliptin) – Daiichi Sankyo and Mitsubishi Tanabe 27
3.3 GLP-1 Agonists 28
3.3.1 Byetta and Bydureon (exenatide) – Bristol-Myers Squibb 28
3.3.2 Lyxumia (lixisenatide) – Sanofi 29
3.3.3 Victoza (liraglutide) – Novo Nordisk 30
3.4 Sulfonylureas 31
3.4.1 Glimepiride 31
3.4.2 Gliclazide 31
3.5 Thiazolidinediones 32
3.5.1 Actos (pioglitazone) – Takeda Pharmaceuticals Limited 32
3.5.2 Avandia (rosiglitazone) – GlaxoSmithKline 33
3.6 Long-Acting Insulins 34
3.6.1 Lantus (insulin glargine) – Sanofi 34
3.6.2 Levemir (insulin detemir) – Novo Nordisk 35
3.6.3 Tresiba and Ryzodeg (Insulin degludec) – Novo Nordisk 36
3.7 SGLT-2 Inhibitors 37
3.7.1 Forxiga (dapagliflozin) – Bristol-Myers Squibb 37
3.7.2 Invokana (canagliflozin) – Janssen 37
3.8 Heat Map for Marketed Products 38
4 Pipeline for Type 2 Diabetes 41
4.1 Overall Pipeline 41
4.2 Therapeutic Classes 42
4.3 Rate of Attrition 44
4.3.1 Failure Rate by Molecule Type 44
4.3.2 Failure Rate by Therapeutic Class 45
4.4 Reasons for Failure of Developmental Programs 48
4.5 Clinical Trial Duration 48
4.5.1 Duration by Molecule Type 48
4.5.2 Duration by Therapeutic Class 49
4.6 Clinical Trial Size 51
4.6.1 Clinical Trial Size by Molecule Type 52
4.6.2 Clinical Trial Size by Therapeutic Class 53
4.7 Promising Drugs in the Pipeline 55
4.7.1 LY-2189265 (dulaglutide) – Eli Lilly 55
4.7.2 Albiglutide – GlaxoSmithKline 55
4.7.3 LC15-044 (gemigliptin) – LG Life Sciences 56
4.7.4 TAK-875 – Takeda 56
4.7.5 Ipragliflozin – Astellas Pharma 57
4.7.6 LX-4211 – Lexicon Pharmaceuticals 57
4.7.7 Imeglimin – Poxel SA 58
4.7.8 CCX-140-B – ChemoCentryx 58
4.7.9 Semaglutide – Novo Nordisk A/S 59
4.7.10 PC-DAC Exendin-4 – ConjuChem Biotechnologies 59
4.8 Heat Map for Pipeline Products 59
4.9 Conclusion 62
5 Market Forecast to 2019 64
5.1 Global Market 64
5.1.1 Treatment Usage Patterns 64
5.1.2 Market Size 65
5.2 US 66
5.2.1 Treatment Usage Patterns 66
5.2.2 Annual Cost of Therapy 67
5.2.3 Market Size 67
5.3 Top Five Countries of Europe 68
5.3.1 Treatment Usage Patterns 68
5.3.2 Annual Cost of Therapy 69
5.3.3 Market Size 70
5.4 Japan 72
5.4.1 Treatment Usage Patterns 72
5.4.2 Annual Cost of Therapy 72
5.4.3 Market Size 73
5.5 Drivers and Barriers 73
5.5.1 Drivers 73
5.5.2 Barriers 74
6 Deals and Strategic Consolidations 75
6.1 Licensing Deals 75
6.1.1 TransTech Pharma Enters into Licensing Agreement with Forest Laboratories 78
6.1.2 Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma 052 78
6.1.3 Zealand Pharma Enters into a Licensing and Collaboration Agreement with Boehringer Ingelheim 78
6.1.4 Exelixis Enters into Licensing Agreement with Bristol-Myers Squibb for XL475 79
6.1.5 Prosidion Limited Enters into a Licensing Agreement with Eli Lilly and Company 79
6.1.6 Metabolex Enters into Licensing Agreement with Sanofi 79
6.1.7 Wellstat Enters into a License Agreement with Sanofi 79
6.1.8 CureDM and Lankenau Institute Enter into a Licensing Agreement with Sanofi 79
6.1.9 Metabolex Enters into a Development and Licensing Agreement with Janssen Pharmaceuticals 80
6.1.10 Dainippon Sumitomo Pharma Enters into Licensing Agreement with Intercept Pharma for INT-747 80
6.1.11 Ipsen Enters into Licensing Agreement with F. Hoffmann-La Roche for BIM 51077 80
6.1.12 Glenmark Pharma Enters into Licensing Agreement with Merck KGaA 80
6.1.13 Euroscreen Enters into Licensing Agreement with Janssen Pharmaceuticals 81
6.1.14 Phenomix Enters into Licensing Agreement with Chiesi Farmaceutici 81
6.1.15 Otsuka Pharma Enters into Licensing Agreement with Kyowa Hakko Kirin for Saxagliptin 81
6.1.16 Nastech Pharma Enters into Licensing Agreement with Amylin Pharma 81
6.1.17 Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk 81
6.1.18 Array BioPharma Enters into a Licensing Agreement with Amgen 82
6.1.19 Theratechnologies Enters into a Licensing Agreement with OctoPlus 82
6.1.20 Diabetica Enters into a Licensing Agreement with Amylin 82
6.1.21 Celtic Therapeutics Enters into a Licensing Agreement with Bellus Health 82
6.1.22 Aradigm Enters into a Licensing Agreement with Novo Nordisk 83
6.1.23 Santarus Enters into a License Agreement with Shore Therapeutics 83
6.1.24 Depomed Enters into a Licensing Agreement with Boehringer Ingelheim 83
6.1.25 Depomed Enters into a Licensing Agreement with Merck 83
6.1.26 Depomed Enters into a Licensing Agreement with Teva 84
6.2 Co-development Deals 84
6.2.1 Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim 85
6.2.2 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb 86
6.2.3 Metabolex Enters into a Co-development Agreement with Janssen Pharmaceuticals 86
6.2.4 Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide 86
6.2.5 Isis Enters into a Collaboration Agreement with Janssen Pharmaceuticals 86
6.2.6 Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim 87
6.2.7 Intercept Pharma Enters into Co-development Agreement with Servier 87
6.2.8 Transition Therapeutics Enters into an Agreement with Eli Lilly 87
6.2.9 Ambrx Enters into a Co-Development Agreement with Bristol-Myers Squibb 87
6.2.10 Biocompatibles Enters into a Co-Development Agreement with AstraZeneca 88
7 Appendix 89
7.1 All Pipeline Drugs by Stage of Development 89
7.1.1 Discovery 89
7.1.2 Preclinical and IND-filed 91
7.1.3 Phase I 95
7.1.4 Phase II 98
7.1.5 Phase III and Pre-registration 102
7.1.6 Undisclosed 104
7.2 Market Forecasts to 2019 105
7.2.1 Global 105
7.2.2 US 105
7.2.3 UK 106
7.2.4 France 106
7.2.5 Germany 107
7.2.6 Italy 107
7.2.7 Spain 108
7.2.8 Japan 108
7.3 Market Definitions 109
7.4 Abbreviations 109
7.5 References for Heat Maps 112
7.6 References 114
7.7 Research Methodology 119
7.7.1 Coverage 119
7.7.2 Secondary Research 120
7.7.3 Primary Research 120
7.8 Therapeutic Landscape 121
7.9 Epidemiology-based Forecasting 121
7.10 Market Size by Geography 122
7.11 Geographical Landscape 123
7.12 Pipeline Analysis 123
7.13 Expert Panel Validation 123
7.14 Contact Us 123
7.15 Disclaimer 123

List of Tables

Table 1: The Relationship between HbA1c and Mean Blood Glucose 15
Table 2: Pipeline Drugs (Discovery) 89
Table 3: Pipeline Drugs (Preclinical and IND-filed) 91
Table 4: Pipeline Drugs (Phase I) 95
Table 5: Pipeline Drugs (Phase II) 98
Table 6: Pipeline Drugs (Phase III) 102
Table 7: Pipeline Drugs (Undisclosed stage of development) 104
Table 8: Type 2 Diabetes Therapeutics Market, Global, Market Forecast, 2012–2019 105
Table 9: Type 2 Diabetes Therapeutics Market, US, Market Forecast, 2012–2019 105
Table 10: Type 2 Diabetes Therapeutics Market, UK, Market Forecast, 2012–2019 106
Table 11: Type 2 Diabetes Therapeutics Market, France, Market Forecast, 2012–2019 106
Table 12: Type 2 Diabetes Therapeutics Market, Germany, Market Forecast, 2012–2019 107
Table 13: Type 2 Diabetes Therapeutics Market, Italy, Market Forecast, 2012–2019 107
Table 14: Type 2 Diabetes Therapeutics Market, Spain, Market Forecast, 2012–2019 108
Table 15: Type 2 Diabetes Therapeutics Market, Japan, Market Forecast, 2012–2019 108
Table 16: Type 2 Diabetes Therapeutics Market, Global, References for Heat Maps, 2013 112

List of Figures

Figure 1: Type 2 Diabetes Therapeutics Market, Global, Composite Treatment Algorithm, 2013 17
Figure 2: Type 2 Diabetes Therapeutics Market, Global, Sales of Januvia and Janumet ($m), 2006-2012 23
Figure 3: Type 2 Diabetes Therapeutics Market, Global, Sales of Onglyza ($m), 2009-2012 25
Figure 4: Type 2 Diabetes Therapeutics Market, Global, Sales of Galvus ($m), 2007–2012 26
Figure 5: Type 2 Diabetes Therapeutics Market, Global, Sales of Byetta ($m), 2005–2010 28
Figure 6: Type 2 Diabetes Therapeutics Market, Global, Sales of Victoza ($m), 2009–2012 30
Figure 7: Type 2 Diabetes Therapeutics Market, Global, Sales of Actos ($m), 2003-2011 32
Figure 8: Type 2 Diabetes Therapeutics Market, Global, Sales of Avandia ($m), 1999–2012 33
Figure 9: Type 2 Diabetes Therapeutics Market, Global, Sales of Lantus ($m), 2003-2012 34
Figure 10: Type 2 Diabetes Therapeutics Market, Global, Sales of Levemir (As reported by Novo Nordisk), 2008-2012 35
Figure 11: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013 39
Figure 12: Type 2 Diabetes Therapeutics Market, Global, Sales of Novel Products ($m, Years after Approval), 1998–2012 40
Figure 13: Type 2 Diabetes Therapeutics Pipeline Overview 41
Figure 14: Type 2 Diabetes Therapeutics Market, Global, Therapeutic Classes 42
Figure 15: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Failure Rate (%), 2006–2013 44
Figure 16: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Molecule Type, 2006–2013 45
Figure 17: Type 2 Diabetes Therapeutics Market, Global, Failure Rate by Therapeutic Class, 2006–2013 46
Figure 18: Type 2 Diabetes Therapeutics Market, Global, Reasons for Clinical Trial Failure (%), 2006–2013 48
Figure 19: Type 2 Diabetes Therapeutics Market, Global, Clinical Trial Duration, 2006–2013 49
Figure 20: Type 2 Diabetes Therapeutics Market, Mean Clinical Trial Duration by Therapeutic Class, Global, 2006–2013 50
Figure 21: Type 2 Diabetes Therapeutics Market, Mean and Median Clinical Trial Size, Global, 2006–2013 51
Figure 22: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Molecule Type, Global, 2006–2013 52
Figure 23: Type 2 Diabetes Therapeutics Market, Clinical Trial Size by Therapeutic Class, Global, 2006–2013 53
Figure 24: Type 2 Diabetes Therapeutics Market, Heat Map of Pipeline Products 60
Figure 25: Type 2 Diabetes Therapeutics Market, Global, Heat Map of Marketed Products, 2013 61
Figure 26: Type 2 Diabetes Therapeutics Market, Global, Treatment Usage Patterns ('000), 2012–2019 64
Figure 27: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012–2019 65
Figure 28: Type 2 Diabetes Therapeutics Market, US, Treatment Usage Patterns, 2012–2019 66
Figure 29: Type 2 Diabetes Therapeutics Market, Global, Market Size ($m), 2012–2019 67
Figure 30: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, 2012–2019 68
Figure 31: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2012–2019 69
Figure 32: Type 2 Diabetes Therapeutics Market, Top Five Countries of Europe, Market Size ($m), 2012–2019 71
Figure 33: Type 2 Diabetes Therapeutics Market, Japan, Treatment Usage Patterns, 2012–2019 72
Figure 34: Type 2 Diabetes Therapeutics Market, Japan, Market Size ($m), 2012–2019 73
Figure 35: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, 2006–2013 75
Figure 36: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, 2006–2013 76
Figure 37: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals, 2006–2013 77
Figure 38: Type 2 Diabetes Therapeutics Market, Global, Licensing Deals by Country, 2006–2013 84
Figure 39: Type 2 Diabetes Therapeutics Market, Global, Co-development Deals, 2006–2012 85
Figure 40: GBI Research Market Forecasting Model 122

Read the full report:
Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019
http://www.reportbuyer.com/pharma_healthcare/treatments/type_diabetes_therapeutics_market_2019_shifting_treatment_algorithm_intensified_competition_expected_drive_growth_2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Kubernetes is a new and revolutionary open-sourced system for managing containers across multiple hosts in a cluster. Ansible is a simple IT automation tool for just about any requirement for reproducible environments. In his session at @DevOpsSummit at 18th Cloud Expo, Patrick Galbraith, a principal engineer at HPE, discussed how to build a fully functional Kubernetes cluster on a number of virtual machines or bare-metal hosts. Also included will be a brief demonstration of running a Galera MyS...
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, will share examples from a wide range of industries – includin...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
Unless your company can spend a lot of money on new technology, re-engineering your environment and hiring a comprehensive cybersecurity team, you will most likely move to the cloud or seek external service partnerships. In his session at 18th Cloud Expo, Darren Guccione, CEO of Keeper Security, revealed what you need to know when it comes to encryption in the cloud.
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection. In his session at 18th Cloud Expo, Bradley Holt, a Developer Advocate with IBM Cloud Data Services, discussed...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
"We are the public cloud providers. We are currently providing 50% of the resources they need for doing e-commerce business in China and we are hosting about 60% of mobile gaming in China," explained Yi Zheng, CPO and VP of Engineering at CDS Global Cloud, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.